Page last updated: 2024-12-11
epimedin b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
epimedin B: structure given in first source; from Epimedium sp. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Epimedium | genus | A plant genus of the family BERBERIDACEAE which is used in DRUGS, CHINESE HERBAL. Members contain flavonol glycosides including epimedins, icariin and noricariin.[MeSH] | Berberidaceae | The Barberry plant family of the order Ranunculales, subclass Magnoliidae, class Magnoliopsida. The shrubs have spiny leaves.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5748393 |
| CHEBI ID | 169048 |
| SCHEMBL ID | 3674180 |
| MeSH ID | M0276451 |
Synonyms (20)
| Synonym |
|---|
| AC-6040 |
| 4h-1-benzopyran-4-one, 3-((6-deoxy-2-o-beta-d-xylopyranosyl-alpha-l-mannopyranosyl)oxy)-7-(beta-d-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)- |
| CHEBI:169048 |
| 3-[(2s,3r,4r,5r,6s)-4,5-dihydroxy-6-methyl-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one |
| 110623-73-9 |
| epimedin b |
| epmedin b |
| S9268 |
| AKOS016002028 |
| SCHEMBL3674180 |
| CS-3677 |
| Q-100061 |
| epimedin-b |
| HY-N0259 |
| DTXSID40149341 |
| CCG-270501 |
| MS-31497 |
| 3-[(6-deoxy-2-o-beta-d-xylopyranosyl-alpha-l-mannopyranosyloxy)]-7-(beta-d-glucopyranosyloxy)-5-hydroxy-2-(4-methoxy-phenyl)-8-(3-methylbut-2-en-1-yl)-4h-chromen-4-one |
| A894871 |
| EX-A6792 |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Epimedin B treatment ameliorated MPTP-induced motor dysfunction and alleviated the decreased contents of DA with its metabolites in the striatum and the loss of tyrosine hydroxylase-immunoreactive (TH-IR) neurons in the substantial nigra pars compacta (SNpc)." | ( Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target. Chen, WF; Dong, XL; Hu, ZF; Zhang, M, 2022) | 2.89 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "To study pharmacokinetic characteristics of epimedin A, B, C and icariin after intermuscular administration of Chuankezhi injection to rat." | ( [Pharmacokinetics of epimedin A, B, C and icariin of Chuankezhi injection in rat]. Sun, S; Xu, SJ; Xu, YJ; Yang, L; Yu, JJ; Zhu, YL, 2016) | 0.43 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " Further integrative analysis indicated that bavachin combined with epimedin B affected genes that were not only related to immune system processes, but also to lipid metabolism." | ( Bavachin combined with epimedin B induce idiosyncratic liver injury under immunological stress conditions. Cao, B; Li, C; Li, G; Li, Y; Lin, M; Xiao, X; Xu, J; Zhang, Y, 2023) | 1.46 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Poor bioavailability of prenylated flavonoids results from their poor intrinsic permeation and transporter-mediated efflux." | ( Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo). Chen, Y; Hu, M; Jia, XB; Zhao, YH, 2008) | 0.35 |
| " In summary, our results clearly demonstrate, for the first time, that poor bioavailability of these three prenylated flavonoids is the result of poor intrinsic permeability and efflux by apical efflux transporters." | ( Study on the mechanism of intestinal absorption of epimedins a, B and C in the Caco-2 cell model. Chen, Y; Gao, X; Liu, C; Qu, D; Wang, Y; Zhou, J, 2014) | 0.4 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " With the conversion ratio as the index, the effects of pH value, temperature, reaction time, dosage of enzyme and concentration of substrates on the conversion ratio were detected." | ( [Study on preparation of sagittatoside B with epimedin B converted from cellulase]. Cui, L; Jia, XB; Sun, E; Xu, FJ; Zhang, ZH, 2014) | 0.66 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| flavonoids | Any organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (32)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 19 (59.38) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.78
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.78) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 34 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||